[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"healthy-male-volunteers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:healthy-male-volunteers":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100650263","phase-1-a-study-in-healthy-male-participants-to-compare-how-chf10196-affects-how-the-body-absorbs-and-processes-two-commonly-used-medicines-dabigatran-a-blood-thinner-and-rosuvastatin-a-medicine-used-to-lower-cholesterol-100650263",false,"NCT07744386","A Study in Healthy Male Participants to Compare How CHF10196 Affects How the Body Absorbs and Processes Two Commonly Used Medicines: Dabigatran, a Blood Thinner, and Rosuvastatin, a Medicine Used to Lower Cholesterol","An Open-label, Fixed-sequence, Non-randomized, Drug-drug Interaction Study to Evaluate the Effect of CHF10196 on the Pharmacokinetics of Dabigatran (P-gp Substrate) and Rosuvastatin (BCRP Substrate) in Healthy Male Participants.","Inclusion Criteria:\n\n* Healthy male participants aged 18 to 55 years\n* Body mass index between 18.0 and 30.0 kg\u002Fm²\n* Non-smokers or ex-smokers (\\\u003C5 pack-years)\n* Clinically healthy based on medical history and examination\n* Vital signs and ECG within normal limits\n* Willing and able to comply with study procedures\n\nExclusion Criteria:\n\n* Use of prohibited concomitant medications\n* Participation in another clinical study within 3 months\n* Clinically relevant medical conditions\n* Abnormal laboratory values\n* Positive HIV, hepatitis B, or hepatitis C\n* History of bleeding disorders\n* Drug or alcohol abuse\n* Use of nicotine-containing products within defined period\n* Recent COVID-19 infection",true,"MALE","18 Years","55 Years",{"count":21,"type":22},24,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The purpose of this study is to assess the potential drug-drug interaction of CHF10196 (a dipeptidyl peptidase 1 inhibitor) and its metabolite on the pharmacokinetics of dabigatran (a P-glycoprotein substrate) and Rosuvastatin (a breast cancer resistant protein substrate) in healthy male participants.",[28],"Healthy Male Volunteers",[30,31,32,33],"pharmacokinetics","CHF10196","DDI","Dipeptidyl Peptidase 1 (DPP1) inhibitor","NOT_YET_RECRUITING","2026-07-29",{"date":37,"type":38},"2026-08-04","ACTUAL",{"date":40,"type":22},"2026-10-27",{"date":42,"type":22},"2028-12-15",{"name":44,"class":45},"Chiesi Farmaceutici S.p.A.","INDUSTRY"]